Enlivex Therapeutics Ltd.

NasdaqCM:ENLV Stock Report

Market Cap: US$22.9m

Enlivex Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Oren Hershkovitz

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5yrs
CEO ownership0.1%
Management average tenure5yrs
Board average tenure2yrs

Recent management updates

Recent updates

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Apr 04
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Dec 13
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Jul 25
Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Apr 05
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Nov 16
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 30

Enlivex to gets US patent covering use of cell therapy Allocetra

Sep 06

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Aug 29

Envilex Therapeutics reports Q2 results

Aug 22

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Jul 08
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Jul 06

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Mar 23
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Nov 25
Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Aug 12
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy

Jun 15

Enlivex issued new Canadian patent for Allocetra immunotherapy

Jun 01

We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn

Apr 29
We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn

Enlivex shares rise 20% on positive Allocetra data in COVID-19

Feb 03

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Jan 11
Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

Nov 19
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

CEO Compensation Analysis

How has Oren Hershkovitz's remuneration changed compared to Enlivex Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$22m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023n/an/a

-US$29m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022n/an/a

-US$31m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$26m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021n/an/a

-US$14m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020n/an/a

-US$12m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$296kUS$38k

-US$10m

Compensation vs Market: Insufficient data to establish whether Oren's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Oren's compensation with company performance.


CEO

Oren Hershkovitz (47 yo)

5yrs

Tenure

US$295,600

Compensation

Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...


Leadership Team

NamePositionTenureCompensationOwnership
Shai Novik
Executive Chairman10.8yrsUS$536.00k3.62%
$ 828.2k
Oren Hershkovitz
Chief Executive Officer5yrsUS$295.60k0.12%
$ 27.3k
Shachar Shlosberger
Chief Financial Officer8.8yrsUS$132.00k0.0088%
$ 2.0k
Veronique Amor-Baroukh
Senior Director of Operations2.8yrsno datano data
Sigal Arad
Director of HR2.8yrsno datano data

5.0yrs

Average Tenure

47yo

Average Age

Experienced Management: ENLV's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shai Novik
Executive Chairman10.8yrsUS$536.00k3.62%
$ 828.2k
Andrew Singer
Independent Director1.6yrsno datano data
Abraham Havron
Independent Director10.8yrsno data0.85%
$ 193.9k
Mitchell Levy
Clinical Advisorno datano datano data
Roger Pomerantz
Independent Vice Chairman of the Board2.5yrsno data0%
$ 0
Brian Schwartz
Director3.9yrsno data0.013%
$ 2.9k
Clifford Deutschman
Clinical Advisorno datano datano data
David Hunter
Clinical Advisorless than a yearno datano data
Bruno Francois
Clinical Advisorless than a yearno datano data
Gili Hart
Independent Director10.8yrsno data0.024%
$ 5.4k
Ali Mobasheri
Clinical Advisorless than a yearno datano data
Tobias Winkler
Clinical Advisorless than a yearno datano data

2.0yrs

Average Tenure

60yo

Average Age

Experienced Board: ENLV's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.